ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

MRKR Marker Therapeutics Inc

4,27
0,22 (5,43%)
Zuletzt aktualisiert: 20:08:53
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Marker Therapeutics Inc MRKR NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,22 5,43% 4,27 20:08:53
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
4,05 4,05 4,27 4,05
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.4.202413:00GLOBEPrincipal Investigator from City of Hope National Medical..
25.3.202422:45GLOBEMarker Therapeutics Reports Year-End 2023 Corporate and..
22.3.202417:30GLOBEMarker Therapeutics to Present at the H.C. Wainwright 2nd..
01.3.202414:02EDGAR2Form 8-K - Current report
26.2.202413:58EDGAR2Form 8-K - Current report
22.1.202413:30GLOBEMarker Therapeutics Receives Approval from United States..
08.1.202414:30EDGAR2Form 8-K - Current report
08.1.202414:24GLOBEMarker Therapeutics Announces Clinical Program Updates and..
21.12.202317:00GLOBEMarker Therapeutics Announces Participation in Biotech..
11.12.202313:35EDGAR2Form 8-K - Current report
11.12.202313:00GLOBEMarker Therapeutics Announces Sustained Complete Response in..
20.11.202322:37EDGAR2Form 8-K - Current report
09.11.202323:03EDGAR2Form 8-K - Current report
09.11.202323:00GLOBEMarker Therapeutics Reports Third Quarter 2023 Financial..
09.11.202322:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11.9.202313:10EDGAR2Form 8-K - Current report
11.9.202313:00GLOBEMarker Therapeutics Announces Complete Response in First..
30.8.202314:00GLOBEMarker Therapeutics to Present at the H.C. Wainwright 25th..
14.8.202322:37EDGAR2Form 8-K - Current report
14.8.202322:30GLOBEMarker Therapeutics Reports Second Quarter 2023 Financial..
14.8.202322:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.8.202313:22EDGAR2Form 8-K - Current report
07.8.202313:00GLOBEMarker Therapeutics Reports Non-Clinical Proof-of-Concept..
26.7.202313:00GLOBEMarker Therapeutics to Participate in Virtual Roundtable..
10.7.202313:09EDGAR2Form 8-K - Current report
10.7.202313:00GLOBEEuropean Medicines Agency Grants Orphan Drug Designation for..
05.7.202322:22EDGAR2Form 3 - Initial statement of beneficial ownership of..
03.7.202322:05EDGAR2Form 8-K - Current report
30.6.202322:05EDGAR2Form 8-K - Current report
26.6.202313:00GLOBEMarker Therapeutics Reports MT-401 Non-Clinical Data in AML..
12.6.202313:00GLOBEMarker Therapeutics Announces First Lymphoma Patient Treated..
31.5.202312:30GLOBEMarker Therapeutics Reports Pre-Clinical Data of its MT-601..
08.5.202313:30GLOBEMarker Therapeutics Appoints Monic Stuart, M.D., as Chief..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock